| Functional roles of enhancer RNAs for oestrogen-dependent transcriptional activation W Li, D Notani, Q Ma, B Tanasa, E Nunez, AY Chen, D Merkurjev, ... Nature 498 (7455), 516-520, 2013 | 1031 | 2013 |
| Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome KR Engelhardt, S McGhee, S Winkler, A Sassi, C Woellner, ... Journal of Allergy and Clinical Immunology 124 (6), 1289-1302. e4, 2009 | 565 | 2009 |
| DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load H Jung, HS Kim, JY Kim, JM Sun, JS Ahn, MJ Ahn, K Park, M Esteller, ... Nature communications 10 (1), 4278, 2019 | 278 | 2019 |
| Caffeic acid and its synthetic derivative CADPE suppress tumor angiogenesis by blocking STAT3-mediated VEGF expression in human renal carcinoma cells JE Jung, HS Kim, CS Lee, DH Park, YN Kim, MJ Lee, JW Lee, JW Park, ... Carcinogenesis 28 (8), 1780-1787, 2007 | 156 | 2007 |
| STAT3 inhibits the degradation of HIF-1α by pVHL-mediated ubiquitination JE Jung, HS Kim, CS Lee, YJ Shin, YN Kim, GH Kang, TY Kim, YS Juhnn, ... Experimental & molecular medicine 40 (5), 479-485, 2008 | 146 | 2008 |
| Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice SH Lee, SY Cho, Y Yoon, C Park, J Sohn, JJ Jeong, BN Jeon, M Jang, ... Nature Microbiology 6 (3), 277-288, 2021 | 136 | 2021 |
| Pathogenicity of a disease-associated human IL-4 receptor allele in experimental asthma R Tachdjian, C Mathias, S Al Khatib, PJ Bryce, HS Kim, F Blaeser, ... Journal of Experimental Medicine 206 (10), 2191-2204, 2009 | 99 | 2009 |
| HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L) 1 blockade in advanced non-small-cell lung cancer patients JH Shim, HS Kim, H Cha, S Kim, TM Kim, V Anagnostou, YL Choi, ... Annals of Oncology 31 (7), 902-911, 2020 | 94 | 2020 |
| Ethyl pyruvate has an anti-inflammatory effect by inhibiting ROS-dependent STAT signaling in activated microglia. HS Kim, IH Cho, JE Kim, YJ Shin, JH Jeon, Y Kim, YM Yang, KH Lee, ... Free radical biology & medicine 45 (7), 950-963, 2008 | 93 | 2008 |
| Comprehensive clinical and genetic characterization of hyperprogression based on volumetry in advanced non–small cell lung cancer treated with immune checkpoint inhibitor Y Kim, CH Kim, HY Lee, SH Lee, HS Kim, S Lee, H Cha, S Hong, K Kim, ... Journal of Thoracic Oncology 14 (9), 1608-1618, 2019 | 84 | 2019 |
| In vivo regulation of the allergic response by the IL-4 receptor α chain immunoreceptor tyrosine-based inhibitory motif R Tachdjian, S Al Khatib, A Schwinglshackl, HS Kim, A Chen, J Blasioli, ... Journal of Allergy and Clinical Immunology 125 (5), 1128-1136. e8, 2010 | 81 | 2010 |
| LYR71, a derivative of trimeric resveratrol, inhibits tumorigenesis by blocking STAT3-mediated matrix metalloproteinase 9 expression JE Kim, HS Kim, YJ Shin, CS Lee, C Won, S Lee, JW Lee, Y Kim, JS Kang, ... Experimental & molecular medicine 40 (5), 514-522, 2008 | 74 | 2008 |
| 8-hydroxydeoxyguanosine suppresses NO production and COX-2 activity via Rac1/STATs signaling in LPS-induced brain microglia HS Kim, SK Ye, IH Cho, JE Jung, DH Kim, S Choi, YS Kim, CG Park, ... Free Radical Biology and Medicine 41 (9), 1392-1403, 2006 | 66 | 2006 |
| Anti-inflammatory effects of 8-hydroxydeoxyguanosine in LPS-induced microglia activation: suppression of STAT3-mediated intercellular adhesion molecule-1 expression DH Kim, IH Cho, HS Kim, JE Jung, JE Kim, KH Lee, T Park, YM Yang, ... Experimental & molecular medicine 38 (4), 417-427, 2006 | 44 | 2006 |
| Pluripotency factors functionally premark cell-type-restricted enhancers in ES cells HS Kim, Y Tan, W Ma, D Merkurjev, E Destici, Q Ma, T Suter, K Ohgi, ... Nature 556 (7702), 510-514, 2018 | 43 | 2018 |
| ZNF224, Krüppel like zinc finger protein, induces cell growth and apoptosis-resistance by down-regulation of p21 and p53 via miR-663a JG Cho, S Park, CH Lim, HS Kim, SY Song, TY Roh, JH Sung, W Suh, ... Oncotarget 7 (21), 31177, 2016 | 41 | 2016 |
| Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity K Kim, HS Kim, JY Kim, H Jung, JM Sun, JS Ahn, MJ Ahn, K Park, SH Lee, ... Nature communications 11 (1), 951, 2020 | 38 | 2020 |
| Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing HS Kim, H Cha, J Kim, WY Park, YL Choi, JM Sun, JS Ahn, MJ Ahn, ... European Journal of Cancer 120, 65-74, 2019 | 33 | 2019 |
| Genomic landscape of acquired resistance to third‐generation EGFR tyrosine kinase inhibitors in EGFR T790M‐mutant non–small cell lung cancer J Lee, HS Kim, B Lee, HK Kim, JM Sun, JS Ahn, MJ Ahn, K Park, SH Lee Cancer 126 (11), 2704-2712, 2020 | 29 | 2020 |
| Hyperprogression after immunotherapy: Clinical implication and genomic alterations in advanced non-small cell lung cancer patients (NSCLC). Y Kim, CH Kim, HS Kim, JM Sun, JS Ahn, MJ Ahn, SH Lee, HY Lee, ... Journal of Clinical Oncology 36 (15_suppl), 9075-9075, 2018 | 29 | 2018 |
